Trogenix
22 employees on LinkedIn · 6 known investors
Find your way into Trogenix
Trogenix develops precision genetic medicines for cancer treatment using proprietary Synthetic Super-Enhancers technology delivered via AAV vectors, targeting solid tumors with personalized in situ vaccinations. The company focuses on oncology with applications in regenerative medicine, beginning with glioblastoma.
Investors · 6
ACADEMY INVESTORArlington
LongeVCWashington D.C.
4BIO CapitalreportedLondon
AIN VenturesreportedNew York · $500K – $1M
.jpeg){kind=logo}
IQ CapitalreportedLondon · $1M – $40M
Also in the syndicate · 1
Eli Lilly
Funding
SEC filings, press & company announcements$95M disclosed across 1 of 2 rounds · 2025
- $95MSeries AOct 2025 · 4 sources
Eli Lilly
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Trogenix do?
- Trogenix develops precision genetic medicines for cancer treatment using proprietary Synthetic Super-Enhancers technology delivered via AAV vectors, targeting solid tumors with personalized in situ vaccinations. The company focuses on oncology with applications in regenerative medicine, beginning with glioblastoma.
- Who are Trogenix's investors?
- Trogenix's investors include ACADEMY INVESTOR, LongeVC, 4BIO Capital, AIN Ventures, IQ Capital.
- How much funding has Trogenix raised?
- Trogenix has disclosed $95M raised across 1 of its 2 known rounds.